Teva Pharmaceuticals To Pay 450 Million To Settle Kickback Allegations Under the civil settlement announced today, teva agreed to resolve allegations that the benefits it received under its price fixing scheme constituted illegal kickbacks. teva will pay collectively $450 million to resolve the two kickback schemes. Teva pharmaceuticals usa inc. (teva usa) and teva neuroscience inc. (collectively, teva) have agreed to pay $450 million to resolve two matters that allege teva violated the anti kickback statute (aks) and the false claims act (fca).
Teva Pharmaceuticals Agrees To Pay 450m To Settle Kickback Allegations On october 10, the us department of justice (doj) announced that teva pharmaceuticals usa inc. and teva neuroscience inc. will pay $450 million to resolve two claims alleging teva violated the anti kickback statute (aks) and false claims act (fca). Generic drug manufacturer teva pharmaceuticals has settled two sets of allegations brought by the department of justice (doj) that it conspired to fix prices through an illegal kickback scheme. the company has agreed to pay a $450 million fine to resolve the related cases. Teva pharmaceuticals usa inc. and teva neuroscience inc., collectively known as teva, have agreed to a $450 million settlement to resolve allegations of violating the anti kickback statute (aks) and the false claims act (fca). Teva pharmaceuticals usa and teva neuroscience have agreed to pay a combined $450 million to resolve claims that the company violated the country’s anti kickback statute (aks) and the false.
Teva Pharmaceuticals Pays 450 Million To Settle Anti Kickback And Teva pharmaceuticals usa inc. and teva neuroscience inc., collectively known as teva, have agreed to a $450 million settlement to resolve allegations of violating the anti kickback statute (aks) and the false claims act (fca). Teva pharmaceuticals usa and teva neuroscience have agreed to pay a combined $450 million to resolve claims that the company violated the country’s anti kickback statute (aks) and the false. Teva pharmaceuticals usa inc. and teva neuroscience inc. have agreed to pay $450 million to resolve allegations that they violated the anti kickback statute (aks) and the false claims act (fca), the department of justice (doj) announced today. Teva pharmaceuticals usa inc. (teva usa) and teva neuroscience inc. (collectively, teva) have agreed to pay $450 million to resolve two matters that allege teva violated the anti kickback statute (aks) and the false claims act (fca). Under the civil settlement announced on october 10, 2024, teva agreed to resolve allegations that the benefits it received under its price fixing scheme constituted illegal kickbacks. teva will pay collectively $450 million to resolve the two kickback schemes. Under the civil settlement announced today, teva agreed to resolve allegations that the benefits it received under its price fixing scheme constituted illegal kickbacks. teva will pay collectively $450 million to resolve the two kickback schemes.
Comments are closed.